nach oben

Erschienen in:

22.07.2022 | original Article

Kynurenines in polycystic kidney disease

verfasst von: Jost Klawitter, Matthew J. Jackson, Peter H. Smith, Katharina Hopp, Michel Chonchol, Berenice Y. Gitomer, Melissa A. Cadnapaphornchai, Uwe Christians, Jelena Klawitter

Erschienen in: Journal of Nephrology | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Abstract

Background

Autosomal dominant polycystic kidney disease (ADPKD) is a common hereditary disorder, characterized by kidney cyst formation. A major pathological feature of ADPKD is the development of interstitial inflammation. Due to its role in inflammation and oxidative stress, tryptophan metabolism and related kynurenines may have relevance in ADPKD.

Methods

Data were collected from a well-characterized longitudinal cohort of pediatric and adult patients with ADPKD and compared to age-matched healthy subjects. To evaluate the role of kynurenines in ADPKD severity and progression, we investigated their association with height-corrected total kidney volume (HtTKV) and kidney function (estimated glomerular filtration rate (eGFR)). Key tryptophan metabolites were measured in plasma using a validated liquid chromatography-mass spectrometry assay.

Results

There was a significant accumulation of kynurenine and kynurenic acid (KYNA) in children and adults with ADPKD as compared to healthy subjects. Downstream kynurenines continued to accumulate in adults with ADPKD concurrent with the increase of inflammatory markers IL-6 and MCP-1. Both markers remained unchanged in ADPKD as compared to healthy children, suggesting alternate pathways responsible for the observed rise in kynurenine and KYNA. KYNA and kynurenine/tryptophan positively associated with disease severity (HtTKV or eGFR) in patients with ADPKD. After Bonferroni adjustment, baseline kynurenines did not associate with disease progression (yearly %change in HtTKV or yearly change in eGFR) in this limited number of patients with ADPKD.

Conclusion

Kynurenine metabolism seems dysregulated in ADPKD as compared to healthy subjects. Inhibition of kynurenine production by inhibition of main pathway enzymes could present a novel way to reduce the progression of ADPKD.

Graphical abstract

Ong AC, Wheatley DN (2003) Polycystic kidney disease–the ciliary connection. Lancet 361(9359):774–776CrossRef

Wilson PD (2004) Polycystic kidney disease. N Engl J Med 350(2):151–164CrossRef

Schrier RW (2009) Renal volume, renin-angiotensin-aldosterone system, hypertension, and left ventricular hypertrophy in patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 20(9):1888–1893CrossRef

Karihaloo A, Koraishy F, Huen SC, Lee Y, Merrick D, Caplan MJ et al (2011) Macrophages promote cyst growth in polycystic kidney disease. J Am Soc Nephrol 22(10):1809–1814CrossRef

Swenson-Fields KI, Vivian CJ, Salah SM, Peda JD, Davis BM, van Rooijen N et al (2013) Macrophages promote polycystic kidney disease progression. Kidney Int 83(5):855–864CrossRef

Poyan Mehr A, Tran MT, Ralto KM, Leaf DE, Washco V, Messmer J et al (2018) De novo NAD(+) biosynthetic impairment in acute kidney injury in humans. Nat Med 24(9):1351–1359CrossRef

Minhas PS, Liu L, Moon PK, Joshi AU, Dove C, Mhatre S et al (2019) Macrophage de novo NAD(+) synthesis specifies immune function in aging and inflammation. Nat Immunol 20(1):50–63CrossRef

Munn DH (2006) Indoleamine 2,3-dioxygenase, tumor-induced tolerance and counter-regulation. Curr Opin Immunol 18(2):220–225CrossRef

Zhai L, Spranger S, Binder DC, Gritsina G, Lauing KL, Giles FJ et al (2015) Molecular pathways: targeting IDO1 and other tryptophan dioxygenases for cancer immunotherapy. Clin Cancer Res 21(24):5427–5433CrossRef

10.

Munn DH, Mellor AL (2013) Indoleamine 2,3 dioxygenase and metabolic control of immune responses. Trends Immunol 34(3):137–143CrossRef

11.

Munipally PK, Agraharm SG, Valavala VK, Gundae S, Turlapati NR (2011) Evaluation of indoleamine 2,3-dioxygenase expression and kynurenine pathway metabolites levels in serum samples of diabetic retinopathy patients. Arch Physiol Biochem 117(5):254–258CrossRef

12.

Prendergast GC (2011) Cancer: why tumours eat tryptophan. Nature 478(7368):192–194CrossRef

13.

Debnath S, Velagapudi C, Redus L, Thameem F, Kasinath B, Hura CE et al (2017) Tryptophan metabolism in patients with chronic kidney disease secondary to type 2 diabetes: relationship to inflammatory markers. Int J Tryptophan Res 10:1178646917694600CrossRef

14.

Pawlak K, Domaniewski T, Mysliwiec M, Pawlak D (2009) Kynurenines and oxidative status are independently associated with thrombomodulin and von Willebrand factor levels in patients with end-stage renal disease. Thromb Res 124(4):452–457CrossRef

15.

Pawlak K, Domaniewski T, Mysliwiec M, Pawlak D (2009) The kynurenines are associated with oxidative stress, inflammation and the prevalence of cardiovascular disease in patients with end-stage renal disease. Atherosclerosis 204(1):309–314CrossRef

16.

Pawlak K, Buraczewska-Buczko A, Mysliwiec M, Pawlak D (2010) Hyperfibrinolysis, uPA/suPAR system, kynurenines, and the prevalence of cardiovascular disease in patients with chronic renal failure on conservative treatment. Am J Med Sci 339(1):5–9CrossRef

17.

Schefold JC, Zeden JP, Fotopoulou C, von Haehling S, Pschowski R, Hasper D et al (2009) Increased indoleamine 2,3-dioxygenase (IDO) activity and elevated serum levels of tryptophan catabolites in patients with chronic kidney disease: a possible link between chronic inflammation and uraemic symptoms. Nephrol Dial Transpl 24(6):1901–1908CrossRef

18.

Sallee M, Dou L, Cerini C, Poitevin S, Brunet P, Burtey S (2014) The aryl hydrocarbon receptor-activating effect of uremic toxins from tryptophan metabolism: a new concept to understand cardiovascular complications of chronic kidney disease. Toxins (Basel) 6(3):934–949CrossRef

19.

Kolachalama VB, Shashar M, Alousi F, Shivanna S, Rijal K, Belghasem ME et al (2018) Uremic solute-aryl hydrocarbon receptor-tissue factor axis associates with thrombosis after vascular injury in humans. J Am Soc Nephrol 29(3):1063–1072CrossRef

20.

Cadnapaphornchai MA, George DM, Masoumi A, McFann K, Strain JD, Schrier RW (2011) Effect of statin therapy on disease progression in pediatric ADPKD: design and baseline characteristics of participants. Contemp Clin Trials 32(3):437–445CrossRef

21.

Cadnapaphornchai MA, George DM, McFann K, Wang W, Gitomer B, Strain JD et al (2014) Effect of pravastatin on total kidney volume, left ventricular mass index, and microalbuminuria in pediatric autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. https://doi.org/10.2215/CJN.08350813CrossRef

22.

Schrier RW, Abebe KZ, Perrone RD, Torres VE, Braun WE, Steinman TI et al (2014) Blood pressure in early autosomal dominant polycystic kidney disease. N Engl J Med 371(24):2255–2266CrossRef

23.

Torres VE, Abebe KZ, Chapman AB, Schrier RW, Braun WE, Steinman TI et al (2014) Angiotensin blockade in late autosomal dominant polycystic kidney disease. N Engl J Med 371(24):2267–2276CrossRef

24.

Zhu W, Stevens AP, Dettmer K, Gottfried E, Hoves S, Kreutz M et al (2011) Quantitative profiling of tryptophan metabolites in serum, urine, and cell culture supernatants by liquid chromatography-tandem mass spectrometry. Anal Bioanal Chem 401(10):3249–3261CrossRef

25.

Klawitter J, Klawitter J, McFann K, Pennington AT, Abebe KZ, Brosnahan G et al (2014) Bioactive lipid mediators in polycystic kidney disease. J Lipid Res 55(6):1139–1149CrossRef

26.

Klawitter J, Reed-Gitomer BY, McFann K, Pennington A, Klawitter J, Abebe KZ et al (2014) Endothelial dysfunction and oxidative stress in polycystic kidney disease. Am J Physiol Renal Physiol 307(11):F1198–F1206CrossRef

27.

Wang D, Strandgaard S, Borresen ML, Luo Z, Connors SG, Yan Q et al (2008) Asymmetric dimethylarginine and lipid peroxidation products in early autosomal dominant polycystic kidney disease. Am J Kidney Dis 51(2):184–191CrossRef

28.

Wang D, Strandgaard S, Iversen J, Wilcox CS (2009) Asymmetric dimethylarginine, oxidative stress, and vascular nitric oxide synthase in essential hypertension. Am J Physiol Regul Integr Comp Physiol 296(2):R195-200CrossRef

29.

Menon V, Rudym D, Chandra P, Miskulin D, Perrone R, Sarnak M (2010) Inflammation, oxidative stress, and insulin resistance in polycystic kidney disease. Clin J Am Soc Nephrol 6(1):7–13CrossRef

30.

Klawitter J, McFann K, Pennington AT, Wang W, Klawitter J, Christians U et al (2015) Pravastatin Therapy and Biomarker Changes in Children and Young Adults with Autosomal Dominant Polycystic Kidney Disease. Clin J Am Soc Nephrol 10(9):1534–1541CrossRef

31.

Song P, Ramprasath T, Wang H, Zou MH (2017) Abnormal kynurenine pathway of tryptophan catabolism in cardiovascular diseases. Cell Mol Life Sci 74:2899–2916CrossRef

32.

Niinisalo P, Raitala A, Pertovaara M, Oja SS, Lehtimaki T, Kahonen M et al (2008) Indoleamine 2,3-dioxygenase activity associates with cardiovascular risk factors: the Health 2000 study. Scand J Clin Lab Invest 68(8):767–770CrossRef

33.

Sulo G, Vollset SE, Nygard O, Midttun O, Ueland PM, Eussen SJ et al (2013) Neopterin and kynurenine-tryptophan ratio as predictors of coronary events in older adults, the Hordaland Health Study. Int J Cardiol 168(2):1435–1440CrossRef

34.

Zinellu A, Sotgia S, Mangoni AA, Sanna M, Satta AE, Carru C (2015) Impact of cholesterol lowering treatment on plasma kynurenine and tryptophan concentrations in chronic kidney disease: relationship with oxidative stress improvement. Nutr Metab Cardiovasc Dis 25(2):153–159CrossRef

35.

Rhee EP, Clish CB, Ghorbani A, Larson MG, Elmariah S, McCabe E et al (2013) A Combined epidemiologic and metabolomic approach improves CKD prediction. J Am Soc Nephrol 24(8):1330–1338CrossRef

36.

Baliga MM, Klawitter J, Christians U, Hopp K, Chonchol M, Gitomer BY et al (2021) Metabolic profiling in children and young adults with autosomal dominant polycystic kidney disease. Sci Rep 11(1):6629CrossRef

37.

Grams ME, Tin A, Rebholz CM, Shafi T, Kottgen A, Perrone RD et al (2017) Metabolomic alterations associated with cause of CKD. Clin J Am Soc Nephrol 12(11):1787–1794CrossRef

38.

Wang K, Zelnick LR, Chen Y, Hoofnagle AN, Watnick T, Seliger S et al (2020) Alterations of proximal tubular secretion in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 15(1):80–88CrossRef

Titel: Kynurenines in polycystic kidney disease
verfasst von: Jost Klawitter
Matthew J. Jackson
Peter H. Smith
Katharina Hopp
Michel Chonchol
Berenice Y. Gitomer
Melissa A. Cadnapaphornchai
Uwe Christians
Jelena Klawitter
Publikationsdatum: 22.07.2022
Verlag: Springer International Publishing
Erschienen in: Journal of Nephrology / Ausgabe 1/2023
Print ISSN: 1121-8428
Elektronische ISSN: 1724-6059
DOI: https://doi.org/10.1007/s40620-022-01361-6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Background

Methods

Results

Conclusion

Graphical abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2023

Double glomerulopathies or two-faced janus? A challenging case in the COVID-19 era

Impact of low eGFR on the immune response against COVID-19

Association of hypochloremia with mortality among patients requiring continuous renal replacement therapy

Size doesn’t always matter: the case of a voluminous bladder with a diverticulum in an otherwise healthy subject

Association of combined fractional excretion of phosphate and FGF23 with heart failure and cardiovascular events in moderate and advanced renal disease